Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis
- PMID: 10690531
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis
Abstract
The levels of cysteine proteinase inhibitors stefin A, stefin B, and cystatin C were determined using ELISAs in sera obtained preoperatively from 345 patients with colorectal cancer and in control sera from 125 healthy blood donors. The levels of stefin A and cystatin C were found to be moderately increased in patient sera (1.4-fold and 1.6-fold, respectively; P < 0.0001), whereas the level of stefin B remained statistically unchanged when compared with controls. The medians were 4.3 ng/ml versus 3.2 ng/ml for stefin A, 1.2 ng/ml versus 1.7 ng/ml for stefin B, and 679 ng/ml versus 425 ng/ml for cystatin C. In patient sera, a weak correlation of cystatin C with age (r = 0.34; P < 0.001) and gender (P = 0.01) was found. Stefin A and cystatin C levels were independent of Dukes' stage, whereas stefin B correlated significantly with Dukes' stage, its level being the highest in stage D (P < 0.007). Stefin B and cystatin C correlated with survival, whereas stefin A was not a significant prognostic factor in this study. Using medians as cutoff values, patients with high levels of stefin B and patients with high levels of cystatin C exhibited a significantly higher risk of death than those with low levels of inhibitors (hazard ratio = 1.6; 95% confidence interval, 1.2-2.2; P = 0.002 for stefin B; hazard ratio = 1.3; 95% confidence interval, 1.0-1.8; P = 0.04 for cystatin C). Our results reveal a correlation between high levels of extracellular cysteine proteinase inhibitors and short survival in patients with colorectal cancer, and the data thus support previous studies suggesting a contributing role of protease inhibitors in the progression of cancer.
Similar articles
-
Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.Clin Cancer Res. 1998 Jun;4(6):1511-6. Clin Cancer Res. 1998. PMID: 9626470
-
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.Anticancer Res. 2000 Nov-Dec;20(6D):5195-8. Anticancer Res. 2000. PMID: 11326694
-
Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis.Oncol Rep. 2006 Oct;16(4):647-55. Oncol Rep. 2006. PMID: 16969475
-
The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.Can J Urol. 2008 Apr;15(2):3967-74. Can J Urol. 2008. PMID: 18405443 Review.
-
[Stefin A--potential application in oncological laboratory diagnosis].Pol Merkur Lekarski. 2005 Jul;19(109):86-9. Pol Merkur Lekarski. 2005. PMID: 16194036 Review. Polish.
Cited by
-
Structural Dynamics Investigation of Human Family 1 & 2 Cystatin-Cathepsin L1 Interaction: A Comparison of Binding Modes.PLoS One. 2016 Oct 20;11(10):e0164970. doi: 10.1371/journal.pone.0164970. eCollection 2016. PLoS One. 2016. PMID: 27764212 Free PMC article.
-
Cystatins in immune system.J Cancer. 2013;4(1):45-56. doi: 10.7150/jca.5044. Epub 2012 Dec 20. J Cancer. 2013. PMID: 23386904 Free PMC article.
-
Cystatin superfamily.J Health Care Poor Underserved. 2010 Feb;21(1 Suppl):51-70. doi: 10.1353/hpu.0.0257. J Health Care Poor Underserved. 2010. PMID: 20173285 Free PMC article. Review.
-
Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway.Int J Oncol. 2014 Apr;44(4):1099-106. doi: 10.3892/ijo.2014.2261. Epub 2014 Jan 21. Int J Oncol. 2014. PMID: 24452274 Free PMC article.
-
Aberrant cystatin-C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden.Oncol Lett. 2018 Nov;16(5):5583-5590. doi: 10.3892/ol.2018.9380. Epub 2018 Sep 3. Oncol Lett. 2018. PMID: 30344712 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous